著者 | Watabe Hiroaki, Sato Akira, Akiyama Daiki, Kakefuda Yuki, Adachi Toru, Ojima Eiji, Hoshi Tomoya, Murakoshi Nobuyuki, Ishizu Tomoko, Seo Yoshihiro, Aonuma Kazutaka
---|---
誌名 | Journal of the American College of Cardiology
巻 | 59
号 | 21
ページ | 1881-1888
年 | 2012-05
(C) 2012 by the American College of Cardiology
NOTICE: this is the author's version of a work that was accepted for publication in Journal of the American College of Cardiology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in PUBLICATION, 59(21) 2012. DOI:10.1016/j.jacc.2012.01.051
URL | http://hdl.handle.net/2241/117293

doi: 10.1016/j.jacc.2012.01.051
Impact of Coronary Plaque Composition on Cardiac Troponin Elevation After Percutaneous Coronary Intervention in Stable Angina Pectoris: A Computed Tomography Analysis

Hiroaki Watabe, MD; Akira Sato, MD; Daiki Akiyama, MD; Yuki Kakefuda, MD; Toru Adachi, MD; Eiji Ojima, MD; Tomoya Hoshi, MD; Nobuyuki Murakoshi, MD, PhD; Tomoko Ishizu, MD, PhD; Yoshihiro Seo, MD; and Kazutaka Aonuma, MD, PhD

Cardiovascular Division, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan

Address for correspondence:
Akira Sato, MD, Cardiovascular Division, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan

Tel: +81-29-853-3143
Fax: +81-29-853-3143
E-mail: asato@md.tsukuba.ac.jp

Brief title: Plaque Composition by MDCT and Troponin Elevation

Word count: 4385

Financial support: none
Relationship with industry: none
Abstract

Objectives: We used multidetector computed tomography (MDCT) to study the relation between culprit plaque characteristics and post-percutaneous coronary intervention (PCI) cardiac troponin T (cTnT) elevation.

Background: PCI is often complicated by post-procedural myocardial necrosis manifested by elevated cardiac biomarkers.

Methods: Stable angina patients (n=107) with normal pre-PCI cTnT levels underwent 64-slice MDCT before PCI to evaluate plaque characteristics of culprit lesions. Patients were divided into 2 groups according to presence (Group I, n=36) or absence (Group II, n=71) of post-PCI cTnT elevation ≥3× the upper limit of normal (0.010 ng/mL) at 24 hours after PCI.

Results: CT attenuation values were significantly lower in Group I than in Group II (43.0 [26.5-75.7] vs 94.0 [65.0-109.0] HU, p<0.001). Remodeling index (RI) was significantly greater in Group I than in Group II (1.20 ± 0.18 vs 1.04 ± 0.15, p<0.001). Spotty calcification was observed significantly more frequently in Group I than in Group II (50% vs 11%, p<0.001). Multivariate analysis showed presence of positive remodeling (RI >1.05) (odds ratio [OR], 4.54; 95% confidence interval [CI], 1.36-15.9; p=0.014) and spotty calcification (OR, 4.27; 95% CI, 1.30-14.8; p=0.016) were statistically significant independent predictors for cTnT elevation. For prediction of cTnT elevation, the presence of all 3 variables (CT attenuation value <55 HU, RI >1.05, and spotty calcification) showed a high positive
predictive value of 94%, and their absence showed a high negative predictive value of 90%.

**Conclusions:** MDCT may be useful in detecting which lesions are at high risk for myocardial necrosis after PCI.

**Key Words:** multidetector computed tomography; coronary plaque; troponin; stents.

**Abbreviations and Acronyms**

- ACS  = acute coronary syndrome
- CSA  = cross-sectional area
- cTnT  = cardiac troponin T
- EEM  = external elastic membrane
- IVUS  = intravascular ultrasound
- MDCT = multidetector computed tomography
- PCI  = percutaneous coronary intervention
- PR   = positive vessel remodeling
- RI   = remodeling index
- SAP  = stable angina pectoris
**Introduction**

Percutaneous coronary intervention (PCI) may be complicated by post-procedural myocardial injury/infarction as manifested by elevated cardiac biomarkers such as creatine kinase (CK)-MB or troponin T. The occurrence of post-procedural myocardial injury/infarction has been shown to be associated with worse short- and long-term clinical outcome (1,2) and even mild elevation of cardiac troponin after PCI has been related to a worse prognosis (3).

Intravascular ultrasound (IVUS) has shown that post-procedural myocardial injury/infarction is caused by lesions with ruptured plaques and/or those with a greater plaque burden (4). Virtual histology IVUS also has shown that post-PCI cardiac troponin (cTnT) elevation occurs in lesions with a large necrotic core area and positive vessel remodeling (PR) (5).

Multidetector computed tomography (MDCT) is a promising technique for noninvasive coronary angiography. With the development of MDCT, it is possible not only to detect coronary artery stenosis (6,7) but also to evaluate coronary plaque quality and quantity such as can be done with IVUS (8,9). Motoyama et al. showed that the CT characteristics of culprit lesions in acute coronary syndrome (ACS) included PR, low-attenuation plaques, and spotty calcification (10) and that the patients with these 2 plaque characteristics of PR and low-attenuation plaques on CTA were at a higher risk of developing ACS than were patients without these characteristics during follow-up (11). Recently, Uetani et al. (12) reported that post-procedural myocardial injury/infarction was associated with the volume and fraction of
low-attenuation plaques detected by MDCT. However, a previous study exploring potential prognostic predictors of cardiovascular events on MDCT showed that mixed lesions were associated with adverse events on follow-up (13). Thin-cap fibroatheromas on virtual histology IVUS were most prevalent in mixed plaques, suggesting a higher degree of vulnerability of these mixed plaques on MDCT (14).

Therefore, we hypothesized that the plaque with MDCT characteristics of low attenuation plaques, PR, and spotty calcification has the potential to predict an elevation of cTnT after PCI. The aim of this study was to investigate the clinical value of PR and spotty calcification in conjunction with low-attenuation plaques on MDCT to predict post-PCI cTnT elevation.

Methods

Study Population. The study population comprised 107 patients who were diagnosed as having stable coronary artery disease by 64-slice MDCT before PCI from April 2009 to August 2010 at our institution. We included patients with stable angina pectoris (SAP) with normal pre-PCI cTnT levels (15) and excluded patients with ST-segment elevation myocardial infarction and unstable AP. We also excluded patients with severely calcified lesions, motion artifacts, previously stented lesions, and chronic total occlusions, for which coronary plaque quantity and degree of stenosis are difficult to evaluate by MDCT.

Study Protocol. All patients underwent 64-slice MDCT to evaluate coronary plaque
characteristics of the culprit lesion before PCI and serial measurements of cTnT before PCI and at 24 hours post procedure. According to cTnT blood test results, the patients were divided into 2 groups according to the presence (Group I, n =36) or absence (Group II, n =71) of post-PCI TnT elevation $\geq 3 \times$ the upper limit of normal (0.010 ng/mL) at 24 hours after PCI.

**MDCT Protocol.** Scanning was performed with a Philips Brilliance-64 scanner (Philips Medical Systems, Cleveland, OH) with $64 \times 0.625$-mm detector configuration. Scanning was performed at 120 kV and 600-1050 mA, 0.2 pitch, and with standard or sharp filters. Estimated effective radiation dose was 11 mSv. Reconstruction was routinely performed using a window centered at 75% of the R–R interval to coincide with left ventricular diastasis. A volume of 60 mL of contrast agent (iopamidol 370 mg/mL; Schering AG) was injected intravenously at a rate of 4 mL/s. As soon as the signal density level in the ascending aorta reached a predefined threshold of 100 Hounsfield units (HU), acquisition of CT data and an electrocardiogram trace were automatically started during a 7 to 9-s breath-hold. The patients were given oral metoprolol (20 mg) 1 h before the scheduled scan if their heart rate was $>70$ beats/min, and all patients received sublingual nitroglycerin (0.3 mg) 5 min before the scan.

**MDCT Analysis.** Analysis of the scans was performed using a Brilliance Workspace 3-D workstation (Philips Medical Systems). Images were initially reconstructed at mid-diastolic phase (75% of R–R interval) of the cardiac cycle. In some cases, additional reconstructions were made at different time points of the R–R interval. Each scan was analyzed
independently by 2 experienced readers unaware of the patient’s identity, clinical presentation, biomarker analysis, and PCI procedure. Image display settings for lumen and plaque quantification were determined according to previously published data (16).

We measured the vessel diameter and lesion length, the cross-sectional area (CSA) of the external elastic membrane (EEM) and target lesion, and the lumen CSA of the proximal and distal vessel references using axial images and multiplanar reconstruction images. CT density values of the culprit plaque were measured from at least 3 points, and averaged this. Remodeling index (RI) was defined as the EEM CSA of the target lesion / the average of the EEM CSAs of the proximal and distal references. We assessed adherent calcium deposits in or adjacent to each plaque by determining their presence or absence and morphology as follows according to previously described methods: diffuse, length (L) of calcium burden ≥3/2 of vessel diameter and width ≥2/3 of vessel diameter; medium, length ≥3/2 of vessel diameter and width <2/3 of vessel diameter or length <3/2 of vessel diameter and width ≥2/3 of vessel diameter; spotty, length <3/2 of vessel diameter and width <2/3 of VD (17). We classified the plaque into three types, namely non-calcified, calcified, and mixed plaque (18).

A ring-like enhancement was defined as either the presence of a ring of high attenuation around certain coronary artery plaques or the CT attenuation of a ring presenting higher than those of the adjacent plaque and no greater than 130 HU (19).

**PCI Procedures.** All patients received treatment with aspirin (200 mg/day) and clopidogrel
(75 mg/day) at least 24 h before the procedure. A glycoprotein IIb/IIIa receptor inhibitor is not yet available in Japan. PCI was performed through either the radial or femoral artery using a 6 French catheter. Before starting the procedure, 6000–10000 units of heparin were given intravenously, and the activated clotting time was maintained at >300 s. Once the guide wire passed through the culprit lesion, balloon dilatation or stent placement was performed. The treatment was regarded as successful when the luminal diameter of the target lesion increased by at least by 50%, residual stenosis was less than 30%, and the Thrombolysis In Myocardial Infarction (TIMI) flow was grade 3 (20). Transient no reflow was defined as an angiogram showing a deterioration of coronary flow of TIMI grade 0, 1, or 2 during the procedure, regardless of the timing, and TIMI grade 3 at the final angiogram (21).

**Statistical Analysis.** All data are expressed as the mean ± SD or median and interquartile range for non-normally distributed data. Comparisons of continuous variables were analyzed by unpaired *t*-test or Mann-Whitney *U* test according to the data distribution. Comparisons of categorical variables between groups were performed by chi-square test without correction for multiplicity. Inter- and intraobserver agreements were performed by linear regression analyses for continuous variables and kappa (κ) test for categorical variables. Receiver-operating characteristic (ROC) analysis was used to determine optimal cut-off values of CT attenuation value and RI for prediction of post-PCI cTnT elevation. The best cut-off value was defined as the point with the highest sum of sensitivity and specificity.
Results displayed for univariate analysis were based on clinically relevant and laboratory-based variables and lesion characteristics. Multivariate logistic regression analysis was then developed to calculate odds ratios (ORs) and 95% confidence intervals (CIs). We performed stepwise forward selection considering any valuables with values of \( p < 0.20 \) to identify potential risk factors for post-PCI cTnT elevation. The sensitivity, specificity, positive and negative predictive values (PPV and NPV), and diagnostic accuracy of the CT characteristics alone or in combination were calculated for prediction of post-PCI cTnT elevation. A \( p \) value of \(<0.05\) was considered to indicate statistical significance.

**Results**

**Patient, Lesion, and Procedural Characteristics.** Patients were divided into 2 groups according to the presence (Group I, \( n = 36 \)) or absence (Group II, \( n = 71 \)) of post-PCI cTnT elevation \( \geq 3\times \) the upper limit of normal (0.010 ng/mL) at 24 hours after PCI. Baseline patient characteristics are summarized in Table 1. There were no statistically significant differences in the clinical characteristics and medications between the two groups. The median post-PCI cTnT levels were significantly higher in patients in Group I than in Group II (0.088 [0.037-0.289] vs 0.010 [0.010-0.014] ng/mL, \( p<0.001 \)). Angiographic findings and procedural results are summarized in Table 2. All lesions were treated with stent implantation. There were no statistically significant differences in target vessels, type B2/C lesions, bifurcation lesions, number of stents implanted, and stent size between the two groups.
Transient no reflow was observed significantly more frequently in Group I than in Group II (16% vs 2%, p = 0.012).

**MDCT Measurements in the Culprit Lesion.** Representative images from patients in Group I and II are presented in Figure 1 and 2, respectively. Fifty randomly selected lesions were measured by two observers. Inter- and intraobserver measurements of CT attenuation value (r = 0.92, p <0.0001 and r = 0.93, p <0.0001, respectively) and RI (r = 0.83, p <0.0001 and r = 0.87, p <0.0001, respectively) were closely correlated, and mean differences in CT attenuation value (0.75 ± 1.58 HU and 2.09 ± 1.31 HU, respectively) and RI (-0.017 ± 0.013 and 0.004 ± 0.011, respectively) were small. Agreement (κ) for the interpretation of spotty calcification was 0.90 and 0.92, respectively. According to the ROC analysis, the best cutoff points of CT attenuation value was 55 HU, with a sensitivity of 69% and a specificity of 80%, and RI was 1.05, with a sensitivity of 80% and a specificity of 68% for prediction of post-cTnT elevation. Therefore, we defined the CT attenuation value of <55 HU as the lower plaque density and RI of >1.05 as the PR. Lesion characteristics on MDCT are listed in Table 2. The CT attenuation value of the culprit plaque was significantly lower in Group I than in Group II (43.0 [26.5-75.7] vs 94.0 [65.0-109.0] HU, p <0.001), and presence of PR (80% vs 32%, p <0.001), and lesion length (16.7 ± 4.2 vs 14.1 ± 5.1 mm, p =0.012) were significantly greater in Group I than in Group II. The prevalence of any coronary plaque subtype and any calcified subtype with the presence or absence of post-PCI cTnT elevation is in Figure 3.
Mixed plaques (64% vs 31%, p <0.001) and spotty calcification (50% vs 11%, p <0.001) were observed significantly more frequently in Group I than in Group II, whereas noncalcified plaques (33% vs 61%, p <0.001) were observed significantly less frequently in Group I than in Group II. Plaque with ring-like enhancement was observed significantly more frequently in Group I than in Group II (31% vs 11%, p =0.016).

**Univariate and Multivariate Analysis for Prediction of Post-PCI cTnT Elevation.**

Post-PCI cTnT elevation was observed in 36 of the 107 patients (33.6%) in this study. According to the univariate analysis (Table 3), lesion length, PR, CT attenuation, and spotty calcification were significantly associated with post-PCI cTnT elevation. Multiple logistic regression analysis showed that the presence of PR (OR 4.54; 95% CI 1.36-15.9; p = 0.014) and spotty calcification (OR 4.27; 95% CI 1.30-14.8; p = 0.016) were statistically significant independent predictors for post-PCI cTnT elevation after adjustment for multiple confounders.

**Diagnostic Accuracy of CT Characteristics for Prediction of Post-PCI cTnT Elevation.**

The sensitivity, specificity, PPV and NPV, and diagnostic accuracy of each CT characteristic alone or in combination are shown in Table 4. Presence of all 3 characteristics (CT <55 HU, RI >1.05, and spotty calcification) showed a high PPV of 94%, and absence of all 3 showed a high NPV of 90% for predictive value of cTnT elevation.
Discussion

Importantly, our study demonstrated a direct relation between pre-PCI plaque composition by MDCT and PMI in SAP patients. Post-PCI cTnT elevation $\geq 3\times$ the upper limit of normal was observed in 33.6% of patients with SAP. The presence of positive remodeling and spotty calcification were the significant predictors of post-PCI cTnT elevation. For prediction of post-PCI cTnT elevation, the presence of all 3 CT characteristics showed a high PPV of 94%, and their absence offered a high NPV of 90% for the exclusion of culprit lesions by noninvasive MDCT imaging.

Relation Between Plaque Characteristics on MDCT and cTnT Elevation. Cardiac biomarker cTnT is sensitive and specific for detection of myocardial damage. Porto et al. found that the cause of periprocedural myocardial necrosis after PCI was the impairment of flow in coronary side branches and distal embolization of atheromatous or thrombotic materials (22). Therefore, pre-PCI plaque composition may have an impact on myocardial injury/infarction during PCI. However, there are few published data regarding the relation between pre-PCI plaque composition by MDCT and post-PCI cardiac biomarker levels. Nakagawa et al. reported that patients who experienced transient no-reflow during PCI had lower plaque CT density values in culprit lesions (23). Uetani et al. demonstrated that post-procedural myocardial injury was associated with the volume and fraction of low-attenuation plaques by MDCT (12). In the present study, CT attenuation value of $<55$
HU was associated with post-PCI cTnT elevation. While in earlier studies, a mean CT density of 14-47 HU was found in lipid-rich plaque (8, 24, 25), Pohle et al. showed a mean density of 58 HU (median 53) (26) and Leber et al. reported that a low CT density value (49 ± 22 HU) is considered to correspond to soft plaque identified on IVUS (16). This difference most likely results from the natural course of atherosclerotic plaque or slice thickness and contrast medium concentration that affect plaque density measurements (27, 28). It will be possible to use our cutoff point of CT attenuation value <55 HU for prediction of post-PCI cTnT elevation clinically.

**Predictive Value for Detection of cTnT Elevation.** In the present study, PR and spotty calcification were significant predictors of post-PCI cTnT elevation. Furthermore, presence of all 3 CT characteristics (CT attenuation value <55 HU, RI >1.05, and spotty calcification) showed a high PPV of 94%, and their absence showed a high NPV of 90%. PR has been associated with plaque vulnerability in clinical studies. A previous report of an IVUS study confirmed that PR (RI >1.05) was an important factor in the culprit lesion (29). Histopathological characteristics of ruptured plaques showed the same characteristics of the vulnerable plaques. Plaque rupture occurred not only in patients with unstable AP or myocardial infarction but also in those with SAP. The rupture site has larger arterial wall and lumen areas and more PR (30). Another histopathological report showed that coronary plaques with PR had a higher lipid content and macrophage count (31), which indicated
plaque vulnerability. Ehara et al. found by IVUS study that small calcium deposits were present with significant frequency in the culprit lesion segments in patients with ACS (32). Burke et al. reported that autopsy data showed the degree of calcification was greatest for acute and healed plaque ruptures and the least for plaque erosion. Calcification in coronary atherosclerosis is associated with one type of plaque instability, namely plaque rupture (33). The data in the present study showed that some SAP patients have spotty calcification and that plaque with spotty calcification was one of the predictors of post-PCI cTnT elevation. A previous MDCT study showed that mixed lesions were associated with adverse events on follow-up (13). Thin-cap fibroatheromas on virtual histology IVUS were most prevalent in mixed plaques, suggesting a higher degree of vulnerability of these mixed plaques on MDCT (14). In the present study, we found that mixed plaques with low-attenuation plaques, PR, and spotty calcification have the potential to predict an elevation of cTnT after PCI. We also demonstrated that none of the conventional risk factors allowed differentiation between the post-PCI cTnT elevation and the elevation free group. These findings were in agreement with a previous MDCT study by Motoyama et al. (11) and were also supported by recent near-infrared spectroscopy data (34).

**Clinical Implications.** These data suggest that it would be worthwhile to consider the identification of these vulnerable plaques by MDCT before PCI. If the plaque has the characteristics of low plaque density, PR, and spotty calcification, a plan for prevention of
post-PCI cTnT elevation can be made before the PCI procedure. Further efforts to minimize procedural events may require aggressive attempts to prevent distal embolization (35). As for medications, Kawai et al. reported that intravenous administration of nicorandil before PCI can prevent slow coronary flow phenomenon (36). A single high loading dose (80 mg) of atorvastatin administered within 24 hours of PCI reduces the incidence of periprocedural MI in elective PCI (37). Therefore, the use of these medicines during or before the procedure might the possibility of preventing post-procedural myocardial injury/infarction in the perioperative period.

**Study Limitation.** First, we acknowledge that because of the relatively small sample size in the present study, our findings should be confirmed in a larger number of patients. Second, we excluded patients with severely calcified lesions in this study. In general, SAP patients frequently have more severe coronary artery calcification in their coronary arteries than do ACS patients. If we included these patients in this study, it is probable that the occurrence of post-PCI cTnT elevation would be lower than that of our presented data. Third, CT plaque density can be altered by the concentration of the contrast agent administered or by contrast type, regardless of the presence or absence of calcification near the plaque and of the model of CT used. Finally, we consider it necessary to investigate the relation between the MDCT image and histopathology and to confirm the correspondence between these imaging characteristics and histopathologic findings.
Conclusion. The present MDCT study showed that post-PCI cTnT elevation occurred in lesions with low-attenuation plaques, PR, and spotty calcification in patients with SAP. MDCT may play an important role in detecting which lesions are at high risk for myocardial necrosis after PCI.
References


29. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and
direction of arterial remodeling in stable versus unstable coronary syndromes: an


34. Raghunathan D, Abdel-Karim AR, Papayannis AC, et al. Relation between the presence
and extent of coronary lipid core plaques detected by near-infrared spectroscopy with
postpercutaneous coronary intervention myocardial infarction. Am J Cardiol

coronary stenting in patients with stable and unstable angina. Circulation

Figure Legend.

Figure 1. The CT characteristics of a culprit lesion in the 52-year-old male patient with post-PCI TnT elevation $\geq 3 \times$ the upper limit of normal. Coronary angiogram (A) and multiplanar reconstructed image (B) show severe stenosis in the mid right coronary artery. Cross-sectional images show the proximal reference (C), culprit lesion (D), and distal reference (E). The lesion has positive remodeling (RI: remodeling index 1.28), spotty calcification, and low CT density (16 HU). Red circle indicates area of spotty calcification.

Figure 2. The CT characteristics of a culprit lesion in the 51-year-old male patient without post-PCI TnT elevation $\geq 3 \times$ the upper limit of normal. Coronary angiogram (A) and multiplanar reconstructed image (B) show significant stenosis in the mid left anterior descending artery (LAD). Cross-sectional images show the proximal reference (C), culprit lesion (D), and distal reference (E). The lesion has no positive remodeling (remodeling index: 0.98) and CT density is 76 HU.

Figure 3. Percentage of individuals with any plaque subtype (A) and any calcified type (B) according to the presence or absence of post-PCI cardiac troponin T (cTnT) elevation $\geq 3 \times$ the upper limit of normal. NCP = noncalcified plaque; MP = mixed plaque; CP = calcified plaque.
Table 1. Clinical Characteristics of the Study Population

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Group I (cTnT Elevation ≥3×) (n = 36)</th>
<th>Group II (cTnT Elevation &lt;3×) (n = 71)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>64 ± 10</td>
<td>66 ± 9</td>
<td>0.219</td>
</tr>
<tr>
<td>Male sex, (%)</td>
<td>30 (83%)</td>
<td>54 (76%)</td>
<td>0.379</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>22 (61%)</td>
<td>54 (76%)</td>
<td>0.112</td>
</tr>
<tr>
<td>Dyslipidemia (%)</td>
<td>30 (83%)</td>
<td>55 (77%)</td>
<td>0.472</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>17 (47%)</td>
<td>35 (49%)</td>
<td>0.671</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>22 (61%)</td>
<td>50 (70%)</td>
<td>0.147</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dl)</td>
<td>100.4 ± 26.7</td>
<td>92.6 ± 22.9</td>
<td>0.151</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dl)</td>
<td>46.9 ± 17.0</td>
<td>49.5 ± 15.0</td>
<td>0.467</td>
</tr>
<tr>
<td>Triglyceride (mg/dl)</td>
<td>137 (90.5-195)*</td>
<td>129 (82.5-195)*</td>
<td>0.802</td>
</tr>
<tr>
<td>C-reactive protein (mg/l)</td>
<td>1.50 (0.65-3.50)*</td>
<td>1.00 (0.60-2.50)*</td>
<td>0.195</td>
</tr>
<tr>
<td>Medications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-blocker</td>
<td>12 (33%)</td>
<td>26 (37%)</td>
<td>0.737</td>
</tr>
<tr>
<td>ACE-inhibitor/ARB</td>
<td>17 (48%)</td>
<td>34 (49%)</td>
<td>0.953</td>
</tr>
<tr>
<td>Calcium channel blocker</td>
<td>16 (45%)</td>
<td>44 (63%)</td>
<td>0.125</td>
</tr>
<tr>
<td>Statin</td>
<td>23 (64%)</td>
<td>53 (75%)</td>
<td>0.234</td>
</tr>
</tbody>
</table>

Values are presented as mean ± SD except as noted. *Median and interquartile range.

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; cTnT = cardiac troponin T; HDL = high-density lipoprotein; LDL = low-density lipoprotein.
Table 2. Culprit Lesion and Procedural Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Group I (cTnT Elevation ≥3×) (n = 36)</th>
<th>Group II (cTnT Elevation &lt;3×) (n = 71)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target vessel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAD (%)</td>
<td>21 (58%)</td>
<td>37 (52%)</td>
<td>0.541</td>
</tr>
<tr>
<td>RCA (%)</td>
<td>7 (19%)</td>
<td>19 (26%)</td>
<td>0.398</td>
</tr>
<tr>
<td>LCX (%)</td>
<td>8 (22%)</td>
<td>15 (21%)</td>
<td>0.896</td>
</tr>
<tr>
<td>Type B2/C lesion (%)</td>
<td>16 (45%)</td>
<td>30 (43%)</td>
<td>0.789</td>
</tr>
<tr>
<td>Bifurcation (%)</td>
<td>10 (28%)</td>
<td>19 (27%)</td>
<td>0.953</td>
</tr>
<tr>
<td>Procedural characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of stents</td>
<td>1.22 ± 0.50</td>
<td>1.14 ± 0.45</td>
<td>0.373</td>
</tr>
<tr>
<td>Stent size (mm)</td>
<td>2.82 ± 0.36</td>
<td>2.79 ± 0.54</td>
<td>0.789</td>
</tr>
<tr>
<td>Transient no reflow (%)</td>
<td>6 (16%)</td>
<td>2 (3%)</td>
<td>0.012</td>
</tr>
<tr>
<td>MDCT measurements</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lesion EEM (mm²)</td>
<td>15.6 ± 1.1</td>
<td>14.1 ± 0.8</td>
<td>0.252</td>
</tr>
<tr>
<td>Lesion MLA (mm²)</td>
<td>2.62 ± 1.44</td>
<td>2.88 ± 1.27</td>
<td>0.381</td>
</tr>
<tr>
<td>Lesion length (mm)</td>
<td>16.7 ± 4.2</td>
<td>14.1 ± 5.1</td>
<td>0.012</td>
</tr>
<tr>
<td>Remodeling index</td>
<td>1.20 ± 0.18</td>
<td>1.04 ± 0.15</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Positive remodeling (%)</td>
<td>29 (80%)</td>
<td>24 (32%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CT attenuation value (HU)</td>
<td>43.0 (26.5-75.7)*</td>
<td>94.0 (65.0-109.0)*</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ring-like enhancement (%)</td>
<td>11 (31%)</td>
<td>8 (11%)</td>
<td>0.016</td>
</tr>
</tbody>
</table>

Values are presented as mean ± SD except as noted. *Median and interquartile range.

CT = computed tomography; cTnT = cardiac troponin T; EEM = external elastic membrane cross-sectional area; HU = Hounsfield units; LAD = left anterior descending; LCX = left circumflex; MDCT = multidetector computed tomography; MLA = minimum lumen area; RCA = right coronary artery.
Table 3. Univariate and Multivariate Logistic Regression Analyses for Prediction of Cardiac Troponin Elevation

<table>
<thead>
<tr>
<th>Factor</th>
<th>Univariate Analysis</th>
<th></th>
<th>Multivariate Analysis</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
<td>p Value</td>
<td>OR</td>
</tr>
<tr>
<td>Age</td>
<td>1.03</td>
<td>0.98-1.08</td>
<td>0.161</td>
<td>1.02</td>
</tr>
<tr>
<td>EEM</td>
<td>1.04</td>
<td>0.96-1.12</td>
<td>0.272</td>
<td></td>
</tr>
<tr>
<td>Lesion length</td>
<td>1.12</td>
<td>1.02-1.23</td>
<td>0.012</td>
<td>1.07</td>
</tr>
<tr>
<td>RI &gt; 1.05</td>
<td>8.65</td>
<td>3.45-24.2</td>
<td>&lt;0.001</td>
<td>4.54</td>
</tr>
<tr>
<td>CT value &lt; 55 HU</td>
<td>9.25</td>
<td>3.79-24.1</td>
<td>&lt;0.001</td>
<td>2.03</td>
</tr>
<tr>
<td>Spotty calcification</td>
<td>7.04</td>
<td>2.71-19.7</td>
<td>&lt;0.001</td>
<td>4.27</td>
</tr>
<tr>
<td>Log CRP</td>
<td>1.29</td>
<td>0.48-1.22</td>
<td>0.271</td>
<td></td>
</tr>
<tr>
<td>Statin use</td>
<td>0.57</td>
<td>0.22-1.44</td>
<td>0.237</td>
<td></td>
</tr>
</tbody>
</table>

CI = confidence interval; CRP = C-reactive protein; CT = computed tomography; EEM = external elastic membrane cross-sectional area; HU = Hounsfield units; OR = odds ratio; RI = remodeling index.
Table 4. Diagnostic Accuracy of CT Characteristics for Prediction of Cardiac Troponin Elevation

<table>
<thead>
<tr>
<th>Factor</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
<th>Accuracy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT value &lt; 55 HU</td>
<td>69</td>
<td>80</td>
<td>64</td>
<td>84</td>
<td>77</td>
</tr>
<tr>
<td>RI &gt; 1.05</td>
<td>80</td>
<td>68</td>
<td>56</td>
<td>87</td>
<td>72</td>
</tr>
<tr>
<td>Spotty calcification</td>
<td>50</td>
<td>88</td>
<td>69</td>
<td>78</td>
<td>76</td>
</tr>
<tr>
<td>CT value &lt; 55 HU + RI &gt; 1.05</td>
<td>67</td>
<td>85</td>
<td>69</td>
<td>83</td>
<td>79</td>
</tr>
<tr>
<td>CT value &lt; 55 HU + RI &gt; 1.05 + spotty calcification</td>
<td>47</td>
<td>98</td>
<td>94</td>
<td>79</td>
<td>81</td>
</tr>
<tr>
<td>CT value &lt; 55 HU or RI &gt; 1.05</td>
<td>83</td>
<td>63</td>
<td>54</td>
<td>88</td>
<td>70</td>
</tr>
<tr>
<td>CT value &lt; 55 HU or RI &gt; 1.05 + or spotty calcification</td>
<td>86</td>
<td>58</td>
<td>52</td>
<td>90</td>
<td>68</td>
</tr>
</tbody>
</table>

CT = computed tomography; HU = Hounsfield units; RI = remodeling index.
A

P<0.001  P<0.001

NCP MP CP

(%) 100

- cTnT ≥ 3×
- cTnT < 3×